EUVIMEDEUVIMED entdecken
Open Access

Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors

Rishi R Sekar iD, Avinash Maganty iD, Kristian D Stensland iD, Lindsey A Herrel iD

JCO Oncology Practice · 2025

DOI: 10.1200/op.24.00206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Rishi R Sekar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Cancer Survivors, Clinical Trials as Topic, Social Vulnerability, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Community factors and structural barriers may contribute to disparities and underrepresentation in cancer clinical trials. We evaluate the influence of community-level social determinants of health, as measured by the Centers for Disease Control and Prevention Social Vulnerability Index (SVI), on disparities in cancer clinical trial discussion and participation. METHODS We performed a cross-sectional analysis of the 2021 Health Information National Trends Survey-SEER, a representative survey of cancer survivors sampled from three SEER registries. The primary outcomes included patient-reported clinical trial discussion and participation. The primary exposure was county-level SVI, linked to each survey respondent by ZIP code of residence and categorized into quintiles. Survey-weighted bivariate comparisons and multivariable logistic regression were performed to evaluate the association between SVI and clinical trial discussion and participation, adjusting for age, sex, race and ethnicity, education, income, and cancer stage. RESULTS We identified 1,220 respondents residing in 153 counties with a median SVI of 0.41 (IQR, 0.27-0.62), representing a population of over 400,000 cancer survivors on weighted analysis. Of the cohort, 15.1% reported clinical trial discussion and 7.7% reported clinical trial participation. Patients who are most socially vulnerable (fifth quintile of SVI) had significantly lower odds of clinical trial discussion (odds ratio [OR], 0.36 [95% CI, 0.15 to 0.87]; P = .02) and clinical trial participation (OR, 0.15 [95% CI, 0.03 to 0.75]; P = .02) compared with patients who are least socially vulnerable (first quintile of SVI). CONCLUSION These findings suggest interventions to identify socially vulnerable communities for expansion of clinical trial opportunities and infrastructure may be an impactful strategy toward improving diversity and representation in cancer clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer SurvivorsClinical Trials as TopicSocial VulnerabilityNeoplasmsHumansMaleFemaleMiddle AgedCross-Sectional StudiesAgedAdult

Autor:innen und Institutionen

  • Department of Urology, University of Michigan, Ann Arbor, MI.
  • Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI.
  • National Clinician Scholars Program, University of Michigan, Ann Arbor, MI.

ORCID-Profile: Rishi R Sekar, Avinash Maganty, Kristian D Stensland, Lindsey A Herrel

Förderung

  • NCI NIH HHS

Zitieren

APA

Sekar, R. R., Maganty, A., Stensland, K. D., & Herrel, L. A. (2025). Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors. JCO Oncology Practice. https://doi.org/10.1200/op.24.00206

Vancouver

Sekar RR, Maganty A, Stensland KD, Herrel LA. Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors. JCO Oncology Practice. 2025. doi:10.1200/op.24.00206

BibTeX
@article{Sekar2025,
  author = {Sekar, Rishi R and Maganty, Avinash and Stensland, Kristian D and Herrel, Lindsey A},
  title = {Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors},
  journal = {JCO Oncology Practice},
  year = {2025},
  doi = {10.1200/op.24.00206}
}
Kostenlos starten →